A systematic workflow consisting of comparative genomics, metabolic pathways analysis and additional drug prioritization parameters identified 264 proteins of Vibrio cholerae which were predicted to be absent in Homo sapiens. Among these, 40 proteins were identified as essential proteins that could serve as potential drug and vaccine targets. Additional prioritization parameters characterized 11 proteins as vaccine candidates while druggability of each of the identified proteins as evaluated by the Drug Bank database which prioritized 16 proteins suitable for drug targets. As a case study, we built a homology model of one of the potential drug targets, MurA ligase, using MODELLER (9v12) software. The model has been further explored for in silico docking with inhibitors having druggability potential from the Drug Bank database. Results from this study could facilitate selecting V. cholerae proteins for drug design and vaccine production pipelines in future.
Introduction
Cholera is a severe diarrheal disease which occurs most frequently in epidemic form, and is caused by the etiological agent, Vibrio cholerae [1] . Over the past 40 years, cholera remains a serious threat in developing countries where sanitation is poor, health care is limited, and drinking water is unsafe. Without treatment, the cholera case fatality rate can be as high as 70% [2] .
Like most enteric pathogens, V. cholerae possesses several efflux systems that confer resistance to antibiotics and other cytotoxic drugs by extruding them from the cell [3] . Spontaneous chromosomal mutation, conjugative plasmids, SXT elements and integrons also help to confer drug resistance [4] . Recently, many clinical isolates of V. cholerae are multidrug resistant [4] . This strongly indicates the need to search for new therapeutic targets and vaccine candidates that would offer better protection.
In the present post-genomics era, the possibilities of selecting targets using computational approaches with integrated "omics" data such as genomics, proteomics, and metabolomics have been increasing continuously [5] . Amongst these, two in silico methods like comparative and subtractive genomics are being widely used for the prediction and identification of potential drug targets in numerous pathogenic bacteria [5] . This strategy is based on searching for genes/proteins present in the pathogen but absent in the host. Furthermore, along with their non-homologous nature, these genes are essential for the survival of the pathogen and serve as critical components in vital physiochemical and metabolic pathways [6] .
In the present study, we performed an in silico metabolic pathway analysis of V. cholerae and its human host for identification of therapeutic candidates. It is expected that the identified potential drug and vaccine targets will not only expand our understanding on the molecular mechanisms of V. cholerae pathogenesis but also facilitate the production of novel therapeutics.
Results

Identification of metabolic pathways and non-homologous proteins
Using computational comparative and subtractive genomics analysis of different metabolic pathways from V. cholera O1 biovar El Tor N16961 (Fig. 1) , a list of potential drug and vaccine targets were identified. We followed several systematic steps that involved several bioinformatics tools, databases and drug target prioritization parameters, to obtain information about proteins that were present in different metabolic pathways of V. cholerae, but absent in its host, H. sapiens, therefore minimizing chances of any side effects [7] . Such proteins are here termed as 'non-homologous' proteins. Initial information about the metabolic pathways of V. cholerae and its human host is obtained from the KEGG pathway database. At present, KEGG contains information about 100 different metabolic pathways of V. cholerae and 276 metabolic pathways of H. sapiens. A manual two-list comparative analysis is performed for the identification of pathways unique (present in V. cholerae and not in H. sapiens) and pathways common to both V. cholerae and its host H. sapiens. Out of 100 metabolic pathways in V. cholerae, 28 pathways were found to be unique and 72 pathways were found to be common between V. cholerae and H. sapiens (Table S1 ).
Following identification of unique and common pathways in V. cholerae, the next step was to find the non-homologous proteins from the V. cholerae genome. For analysis of such proteins, protein sequences from common and unique pathways were obtained and compared using NCBI BLASTP against the human proteome. The search resulted in identification of 264 proteins from unique pathway that showed no significant similarity with the human proteome (Table S2) .
Identification of non-homologous essential proteins
In this section, we report the computational identification of nonhomologous essential proteins of V. cholerae using the DEG BLASTP analysis. Identification of proteins that are important for its survival, virulence and pathogenicity, is of great importance for disruption of pathogen functions. At present, the DEG (Database of Essential Gene) contains 779 essential genes of V. cholerae [8] . However, it is unknown how many of these gene products are non-homologous to human proteins. Not all the essential proteins are non-homologous in nature. Out of 264 non-homologous proteins, we identified a total of 40 essential non-homologous proteins from V. cholerae (Table 1) .
Sub-cellular localization and drug target prioritization
Until now, we discussed about non-homologous essential proteins of the pathogen using computational comparative and subtractive genomics study. Although this is the major criterion in determining drug target from a pathogen, several other factors are taken into consideration for suitability of drug and vaccine targets. In our study, we focused on parameters such as low molecular weight of a protein, presence of transmembrane helices, availability of 3D structures in PDB and Modbase models and sub-cellular localization of the potential drug and vaccine targets. Availability of 3D structures helps in docking analysis to be carried out for novel drug discoveries and should be considered for future drug design. In silico prediction of sub-cellular localization provides a quick and inexpensive means for obtaining information regarding protein function. Cytoplasmic or membrane localization of the targets determines the ease of purification steps to be followed in experimental studies. It has been considered that proteins with low molecular weight (100-110 kDa) increase the accessibility value of a target protein. In our study, out of 40 essential protein targets, 11 are membrane proteins and rest fall into category of cytoplasmic proteins, as predicted by CELLO v 2.5 [9] and PSORTb [10] (Table 1) . Transmembrane predictions were made by using TMHMM [11] . The TMHMM results were almost in agreement with the sub-cellular localization predictions except two proteins. All these 11 proteins were found to form antigenic peptide epitopes with cleavage probability ranging from 0.6234 to 1.00 and MHC binding score ranging from 0.6129 to 0.9118 (Table S3) . These scores are better than the threshold score of 0.5.These membrane proteins can act as both drug and vaccine targets and the remaining proteins can act as drug targets, which can be exploited for future drug design.
Druggability of therapeutic targets
Druggability of each of the non-homologous essential proteins of V. cholerae was identified by sequence similarity to targets of small molecule drugs by utilizing the Drug Bank database. This led to the identification of 16 V. cholerae proteins that were highly similar to the binding partners of FDA-approved and small experimental molecule drugs (Table S4) .
In summary the computational comparative and subtractive genomic/ proteomic analysis of different metabolic pathways resulted in a step-wise reduction in the number of relevant targets and identification of several proteins of V. cholerae that can be targeted for effective drug design and vaccine development.
Pathways unique to V. cholerae when compared to the host H. sapiens
An important question to be addressed while choosing potential drug targets is whether the biochemical pathway to be targeted is unique to bacteria [12] . The six pathways unique to pathogen include: peptidoglycan biosynthesis, D-alanine metabolism, lipo-polysaccharide biosynthesis, bacterial chemotaxis, bacterial secretion system and V. cholerae pathogenic cycle.
Amongst these pathways, peptidoglycan biosynthesis and D-alanine metabolism are common to all bacterial species, and the cell wall biosynthetic pathways have long been targeted for antimicrobial discovery. The lipopolysaccharide (LPS)-rich outer membrane of V. cholerae provides a protective barrier that insulates these organisms from the action of numerous antibiotics [13] . Inhibition of LPS biosynthesis, leading to a truncated LPS molecule, is a strategy for antibacterial drug development in which this vital cellular structure is weakened [13] . We therefore investigated the lipopolysaccharide biosynthesis, D-alanine metabolism and peptidoglycan biosynthetic pathway.
Lipopolysaccharides (LPS) biosynthesis
Lipopolysaccharides are essential constituent of bacterial endotoxin and define many of the properties of host-parasite interaction. Disruption of early catalytic steps in the biosynthesis of the lipid A through chemical disruption by small-molecule inhibitors of LPS biosynthesis has the potential to be developed into antimicrobial agents themselves or as codrug formulations with antibiotics. Despite this promise, there have been relatively few forays into the development of inhibitors of LPS biosynthetic enzymes, with the exception of the lipid A biosynthetic enzyme LpxC [14] [15] [16] .
In our study we predicted LpxA, LpxB, LpxD and LpxC from LPS biosynthesis pathway as the non-homologous essential proteins that can be selected for novel antibacterial drug discovery. Lipid A biosynthesis occurs in the cytoplasm on the cytosolic surface of the inner membrane and it is catalyzed by nine unique enzymes [17] . The first three enzymes (LpxA, LpxC, and LpxD) in the pathway are essential for lipid A biosynthesis and share no sequence or structural homology with any mammalian proteins [18] . We report 2-hydroxymethyl-6-octylsulfanyl-tetrahydro-pyran-3, 4, 5-triol to be an inhibitor of LpxA enzyme in our study through druggability test. UDP-GlcNAc acyltransferase (LpxA) catalyzes the first step of lipid A biosynthesis, the transfer of the R-3-hydroxyacyl chain from R-3-hydroxyacyl acyl carrier protein (ACP) to the glucosamine 3-OH group of UDP-GlcNAc [18] . Similarly gmhA encoding enzymes, phosphoheptose isomerase was also predicted to be an important therapeutic candidate in the druggability test. The gmhA encoding enzyme is an isomerase which is responsible for biosynthesis of the nucleotide-activated heptose precursors for the inner core assembly. It has been reported in the previous study that defects in the biosynthesis of heptoses results in a dramatic reduction of virulence and increased antibiotic susceptibility in bacteria [19] .
Peptidoglycan biosynthesis
Enzymes from peptidoglycan biosynthesis pathway such as MurA, MurB, MurC, MurG and MurE form good drug target candidates [20] . The peptidoglycan layer of the cell wall serves as a base for lipid-rich capsule. Peptidoglycan or murein is the polymeric mesh of the bacterial cell wall, which plays a critical role in protecting the bacteria against osmotic lysis. Most of the antimicrobial target, steps in the later stage of cell wall biosynthesis. The earlier step in cell wall biosynthesis has not been targeted. To date, only fosfomycin, which targets MurA (NAG enolpyruvate transferase), has been developed as an antibacterial agent [21] . So as a case study, we selected MurA enzyme and performed homology modeling and molecular docking simulation study. MurA enzyme is highly conserved across both Gram-positive and Gram-negative bacteria, is essential for cell survival and has no human homolog [22] .
MurA ligase -a potential broad spectrum target
The Mur enzymes of the peptidoglycan biosynthesis pathway constitute the ideal targets for the design of new classes of antimicrobial inhibitors. MurA ligase of V. cholerae is a 44686 Da protein (UniprotKB entry Q9KP62) of 419 amino acids in length, most likely expressed in the cytoplasm. Based on sequence analysis and similarity with homologous enzymes (such as MurA ligase of V. fischeri − 87% identity), this enzyme is deduced to have amino acid ligase activity, and is believed to be involved in cellular processes like cell cycle, cell division, cell wall organization, and peptidoglycan biosynthesis process.
Homology modeling of MurA ligase
Since the structure of V. cholerae MurA ligase has not been determined experimentally, homology modeling was used to construct a three-dimensional model of the protein. A BLASTP search against the PDB database revealed MurA chain A from V. fischeri in complex with substrate UDP-N-acetylglucosamine and the drug fosfomycin (PDB ID: 3VCY) as the closest homolog, with 87% identity and 99% query coverage (e-value = 0.0). Hence, the V. fischeri protein was used as template for homology modeling. The alignment of the target and template sequences was generated by using the online program Multalin [23] as shown in Fig. 2 . Then the model of MurA ligase was built by Modeller9v12 [24] and using the crystal structure coordinates of the template structure (3VCY). The modeler program uses the spatial constraints determined from the crystal structure, to build a threedimensional model of target protein with the unknown tertiary structure. The quality of the model with lowest DOPE (Discrete Optimized Protein Energy) score (− 50926.24) was then validated with the PROCHECK [25] , ERRAT [26] and Verify3D [27] programs, available at the SAVES server. Ramachandran plot generated by PROCHECK for the best model (Fig. S1 ) shows that not a single residue in the generated structure falls in the disallowed region of the phi-psi dihedral angle plot, while 96.4% residue fall in the most favored region, thus validating the quality of the model. The ERRAT server gives the overall quality factor (expressed as the percentage of the protein for which the calculated error values fall in the 95% rejection limit) of the model as 88.078.The main chain parameter plots for the model were generated using PROCHECK shown in the (Fig. S2) .The plots are for the Ramachandran plot quality, peptide bond planarity, bad non-bonded interactions, C-alpha tetrahedral distortion, main chain hydrogen bond energy and the overall G-factor. Fig. 3 shows the modeled structure of the MurA ligase protein of V. cholerae with active site residues. Further, the template crystal structure, 3VCY, was superimposed on the generated model using the Pymol visualization software [28] . Both the structures were found to be significantly similar in topology, and aligned well with each other, with an RMS value of 0.161 Å. The low overall RMSD reflects the high structural conservation making it a good system for homology modeling. Through this assessment and analysis process, it is concluded that the V. cholerae MurA model generated in the present study is reliable to characterize protein-substrate and protein-ligand interactions and to investigate the relation between the structure and function.
The active site of the protein model, where the reaction to be inhibited takes place, was determined for docking studies. Since no experimental data is available for MurA enzyme, the active site residues of the closest homolog, the V. fischeri protein (PDB ID: 3VCY) were used. The corresponding residues were located in our model and assumed to be a part of the catalytic site of our protein, since both the proteins share high identity, are evolutionarily related, and have the same catalytic function. The residues which are a part of the active site in our model structure are Lys 23, Arg 92, Cys 116, Arg 121, Arg 398.
Docking
The putative active site residues of V. cholerae MurA protein were picked to generate a grid in the centroid of the residues for virtual screening. The experimental small molecules screened from the Drug Bank database were docked with MurA ligase protein model using GLIDE module of Schrodinger [29] . The GLIDE XP docking score (− 13.719 kcal/mol) and the Glide E model score (− 109.126) of the Uridine-Diphosphate-N-Acetyl glucosamine (DB03397), the substrate of MurA enzyme were significantly high ( Table 2 ). Docking pose analysis shows numerous hydrogen bond interactions with the amino acid residues of the protein, many of which were with amino acids that are part of the putative active site Arg 121, Arg 92, and Lys 23 as shown in Fig. 4 .
The next favorable interaction is shown by 3′-1-Carboxy-1-Phosphonooxy-Ethoxy-Uridine-Diphosphate-N-Acetylglucosamanine (tetrahedral intermediate of MurA enzyme) with XP score − 13.581 kcal/mol and having hydrogen bond interaction with the active site residues Arg 398, Arg 121, Lys 23( Fig. S3(d) ). These two natural inhibitors shared the same structural backbone. Fosfomycin, which is a natural product antimicrobial agent for MurA enzyme [30] , is also identified as the as a therapeutic molecule in the druggability test. When this inhibitor was docked against V. cholerae MurA ligase model, it was found to have an XP score of −6.565 kcal/mol and an E model score of 0.000 kcal/mol. The antibiotic showed two hydrogen bond interaction with the active site residues Arg 121 and Arg 92. Fosfomycin inactivates the enzyme by irreversibly binding to the enzyme forming a covalent adducts with the cysteine 115 residues of E. coli MurA [30] . The docking pose of the other screened compounds had good XP score with hydrogen bond interaction with key active site residues (Table 2) . Interestingly these molecules are structurally different from each other. The result from the docking study presents an interesting opportunity for the structure-based design of small-molecule inhibitor of MurA against the recent fosfomycin resistant strains. As a test study, we referred to the previous work in an opportunist bacterial pathogen Acinetobacter baumannii where the model building and lead inhibitor identification were carried out on two essential gene targets, MurA and MurB enzyme. Compounds showing activity against MurA enzyme of other organisms were collected from literature and were docked to the active site residues of the homology model of MurA enzyme by GLIDE software [31] . The inhibitors showed hydrogen bond interaction with the same active site residues such as Lys 22, Arg 398 and Arg 92, as in our case. This test study data is a validation of the docking protocol followed in our system.
D-alanine metabolism
The D-alanine-D-alanine ligase "ddlA" and the alanine racemase "alr" from this pathway have no similarity to any of the host proteins. D-Alanine is a necessary precursor in the bacterial peptidoglycan biosynthetic pathway. The naturally occurring L-isomer is racemized to its D-form through the action of a class of enzymes called alanine racemase. These enzymes are ubiquitous among prokaryotes and are absent in eukaryotes with a few exceptions making them a logical target for the development of antibiotics. Alanine racemase "alr" has in fact been identified as a target by our approach as indicated in Table 1 . In V. cholerae, a dedicated racemase produced D-Met and D-Leu [32] . In our study we identified one alanine racemase inhibitor, the structural D-alanine analogue D-cycloserine, an FDA approved molecule in the druggability test. Designing of inhibitors against the key enzymes in peptidoglycan biosynthesis significantly weakens the structural integrity of the cell wall and leads to osmotic lysis [33] .
Targets from other pathways
Bacterial chemotaxis
A membrane protein, flagellar motor protein; product of motB gene is known to aid bacterial chemotaxis and flagellar assembly that can be regarded as a good vaccine target. The motility protein B (MotB) is a key component of the bacterial flagellar motor. It anchors the MotA/MotB stator ring of the motor to peptidoglycan of the cell wall and forms part of the proton-conducting channel that couples proton flow for generation of the turning force [34] . The motility and chemotaxis are believed to guide V. cholerae to its preferred colonization site within the small intestine for establishment of infection.
Bacterial secretion system
Membrane proteins such as secG, secY and secE identified from bacterial secretion system and protein export are a few other candidates excellent for vaccine design. These preprototein translocase subunits are part of the V. cholerae Sec pathway. SecY, SecE, and SecG form an essential heterotrimeric protein complex that is central to the Sec pathway. This SecYEG complex serves as a transport channel for the movement of protein synthesized in the cytoplasm to the extra cytoplasmic environment. These transport and movement of protein through the SecYEG channel are regulated by cytoplasmic ATPase SecA, via repeated cycles of ATP-binding and hydrolysis. It has been observed that disruption of SecYEG-SecA leads to aggregation of unfolded bacterial proteins in the cytoplasm and triggers a cellular stress response [6] . Therefore, following the biological significance and increasing evidence supporting the therapeutic potential of protein export machinery, we suggest that the development of inhibitors against these proteins holds great therapeutic potential for the treatment of V. cholerae infections. However, one important criterion that must be met so that membrane protein can be a successful vaccine candidate is that the protein must possess surface-exposed and antibody accessible antigenic determinants. All the membrane proteins selected are identified for antigenic peptide epitopes and their binding interaction with MHC class I. Interaction of MHC Class I presented antigens with cytotoxic CD8
+ lymphocytes is one of the potential vaccine induced immune responses and thus, these membrane proteins fulfill the prerequisite of being potent vaccine candidates.
V. cholerae infection
Among the other candidate drug target, Cholera endotoxin B subunit from V. cholerae pathogenic cycle is predicted to be a therapeutic candidate in our study with three dimensional structures available at PDB. The druggability test revealed an experimental small molecule 3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1, 2-Dione (DB03077) as an inhibitor of the predicted drug target (Table S4) .
Discussion
The search for drug targets using computational methods and integrated 'omics' data, such as genomics, proteomics, and metabolomics, has received much attention and has been increasing continuously [35] .Computational genomic approaches have already facilitated the search for potential drug targets against many pathogens [36, 37] .The present study is the first computational analysis of KEGG annotated metabolic pathways that led to identification of several proteins for effective drug design and vaccine development against V. cholerae.
The possibilities of selecting targets using computational approaches with integrated 'omics' data rely on searching for those genes/proteins that are absent in the host and/or non-homologous to the host proteome but present in the pathogen as designing a drug specific to such targets will have an effect only on the pathogen and not any other aspect of the host biology [36] .This promoted us to search nonhomologous proteins of the pathogen against the human proteome and resulted in the identification of 264 proteins of V. cholerae which represent no significant homology.
The potential of the identified non-homologous proteins to be a therapeutic target of a given pathogen gene product is dependent on two broad types of information. First, the role of the gene in the growth and survival of the pathogen defining the essentiality of genes/proteins and second, the likelihood of being able to develop a compound that modulates that target into a drug defining the druggability of the target proteins [38] . There have been several attempts to define or predict essential genes in infectious agents through systematic disruption of candidate genes and transposon mutagenesis. However, for the vast majority of infectious organisms, high throughput experimental interrogation of essentiality is currently not possible, and efforts to define essentiality have been based on bioinformatics predictions. In this study we made an attempt to predict the non-homologous essential proteins of V. cholerae following a similar fashion based on bioinformatics predictions through homology search with the already identified essential gene/protein database from 22 bacteria in the DEG. Advances in genome sequencing, bioinformatics and cheminformatics coupled with experimental data have shown several additional factors such as molecular mass (b110 kDa), sub-cellular localization, whether the protein is transmembrane and availability of 3D structural information that can aid in determining the suitability of therapeutic targets besides identifying the proteins of the pathogen as non-homologous and essential proteins [38] . Proteins with smaller molecular mass were found very likely to be soluble and easier to purify [39] . In our study we found, all the 29 cytoplasmic proteins have a molecular weight less than 110 kDa. Apart from the molecular weight, knowledge about the sub cellular localization of proteins will help to understand the function and can lead to important therapeutics and diagnosis [40] . The membrane localization of 11 proteins from the non-homologous essential proteins identified using CELLO server was in line with the prediction of transmembrane domain by TMHMM server except flagellar motor switch protein and toxin co-regulated pilus biosynthesis protein F (Table 1) . They are regarded as potential vaccine candidates for development of effective vaccine as many of the vaccines that protect by eliciting antibody mediated immunity that appears to be secreted toxins and/or highly expressed, surface exposed molecules [41] .The present comparative genomics approach will help to conduct biological assays by substantially reducing the number of proteins to be tested.
Although V. cholerae is a most widely studied pathogenic bacteria, the availability of very few non-homologous essential protein structure of the pathogen, demarcates skewedness of research areas in V. cholerae. The structural information on protein helps to increase the druggability value by facilitating a structure-based drug design, including homology modeling, docking, virtual screening or pharmacophore-based screening. The second determinant for the potential of a non-homologous protein to be a therapeutic target, the druggability of the protein, was determined with the homology search against the Drug Bank target proteins. The search reduces the testable proteins to 16 that produce a list of different types of drugs in the Drug Bank that bind to proteins of the pathogen. However, the protein sequence similarity search had limitations in that it does not assure the structure or binding pocket congruency with the identified similar proteins.
From the several proteins identified in different unique pathway; we found proteins from bacterial secretion system as vaccine and drug targets. Specific example may include the preprototein translocase subunits (secG, secY and secE). These pathways are critical for growth and survival of the bacteria. Similarly peptidoglycan is the major structural component of the cell wall in Gram-positive and Gram-negative bacteria. Peptidoglycan is a macromolecule consisting of long aminosugar strands cross-linked by short polypeptide chain which plays a critical role in bacteria against osmotic lysis. MurA enzyme which catalyzes the first committed step of bacterial peptidoglycan biosynthesis is a prime candidate for therapeutic intervention.
Homology modeling followed by molecular docking study of the screened molecules from the Drug Bank library revealed that the docking score of Uridine-Diphosphate-N-Acetyl glucosamine is fared better. The molecule may act as a competitive inhibitor based on the structure, and should be tested in vivo, and that further analogs could be generated based on the molecules discovered here. Computational studies like these can provide a rapid approach to identify novel drug targets and develop better drugs against crucial pathogens.
In summary using the computational comparative and subtractive genomic study several proteins in the V. cholerae genome have been identified that can be targeted for effective drug design and vaccine development. As many of the identified drug targets have been reported to play a role in the critical metabolic pathways that regulate bacterial pathogenicity and essential nutrient uptake, a systematic approach to develop drugs against these targets would likely be very promising for the treatment of cholera. This information can lead to significant progress in testing the efficacy of already available antibiotics, in comparison with novel drug development, equally important but more time consuming. It is expected that the drugs developed against identified targets will be specific to the pathogen and of minimal toxicity for the host.
Materials and methods
Identification of host and pathogen metabolic pathways
Through a systematic work flow, this is the first computational and subtractive genomics analysis of different metabolic pathways for the identification of potential drug and vaccine targets in the V. cholerae O1 biovar El Tor N16961 genome (Fig. 1) . We referred to the previous work on comparative/subtractive genomics workflow [5, 6] . For deriving metabolic pathway based information, we used Kyoto Encyclopedia of Genes and Genomes (KEGG) [42] . We extracted the data with reference to the metabolic pathways and identification numbers for the human host and the pathogen and saved them locally. After that, a manual comparison was conducted by searching the name of each individual pathway of V. cholerae against 276 pathways of the host, H. sapiens and the pathway that did not appear in the host but was present in the pathogen, was selected and considered as unique to V. cholerae. The remaining pathways were listed as common pathways (Table S1) . We obtained the proteins and the corresponding amino acid sequences from the Swiss-Prot database [43] .
Identification of non-homologous and essential pathogen proteins
In the beginning of search, proteins from both the unique and common pathways were subjected to BLASTP analysis [44] . We restricted our search to human proteins through the 'select organism' option available under BLASTP parameters. We classified proteins as nonhomologous if they did not have hits below the e-value threshold of 0.005. The criterion for selection-value was based on previous studies [5, 6, 12, 35] . In the second step of our filtering process, all the nonhomologous proteins were further filtered based on the essentiality criteria for V. cholerae. These essential proteins are necessary for growth and replication and therefore form attractive targets for antimicrobial treatments. We referred to the Database of Essential Genes (DEG) [8] for generating information about essential proteins of V. cholerae. Filtering criteria such as e-value cut-off of 10 −10 and a minimum bit score of 100 were used for screening the non-homologous essential proteins of the pathogen. For setting the e-value we referred to the previous work [5, 6] .
Drug target prioritization
There are certain criteria that help in determining suitable drug targets which were evaluated for each of the potential drug targets. This involved calculation of molecular weight (MW) using computational tools and drug targets associated literature available at SwissProt database. Transmembrane predictions were made by TMHMM server [11] , and we searched for the presence of solved 3D structures through Protein Data Bank (PDB) [45] and Mod-Base [46] . Additionally, the membrane proteins were analyzed for MAPPP (MHC-I Antigenic Peptide Processing Prediction) (/http://www.mpiib-berlin.mpg.de/ MAPPP/) with the SYFPEITHY matrix which combines existing prediction tools for proteosomal processing and MHC class I anchoring.
Druggability is another important target prioritization criterion, which is defined as the likelihood of being able to modulate the activity of the protein target with a small-molecule drug [47] . The druggability potential of each of the identified drug targets was calculated by mining the DrugBank contents. The DrugBank database is a unique bioinformatics and chemo-informatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information [48] .The database contains 6811 drug entries including 1528 FDAapproved small molecule drugs, 150 FDA-approved biotech (protein/ peptide) drugs, 87 nutraceuticals and 5080 experimental drugs. Additionally, 4294 non-redundant protein (i.e. drug target/enzyme/ transporter/carrier) sequences are linked to these drug entries. The default parameters for BLASTP were used to line up the potential drug targets from V. cholerae against the list of protein targets of compounds found within the Drug Bank. The selection criteria on BLASTP results is based on previous study [49] , that is alignments with e-values less significant than 1 × 10 −25 were removed.
Homology modeling
A homology model for UDP-N-acetyl glucosamine 1-carboxyvinyl transferase (MurA) of V. cholerae was built using MODELLER (9v12) programme [24] . A BLASTP search of the V. cholerae MurA sequence against the proteins available in the PDB database was carried out. Based on the sequence identity and query coverage, MurA ligase from V. fischeri (PDB ID: 3VCY) was chosen as the most suitable template for homology modeling. The primary sequences of the two proteins were aligned using the Multalin program. The quality of the model was verified using PROCHECK, a protein structure verification program. The model was used for molecular docking study.
Docking study
The molecules which passed the druggability test from the Drug Bank database were selected for docking study to determine the molecular interaction in the enzyme active site.
Preparation of the target protein model
The three dimensional structure model of MurA enzyme of V. cholerae was prepared for small molecule docking using the Protein Preparation Wizard module of Schrodinger Software Suite 2010. The program removes all of water molecules, adds hydrogen atoms to the protein structure and assigns all of atom force field (OPSL-2005) charges and atom types. Minimizations were performed until the average root mean square deviation of non-hydrogen atoms reached 0.3 Å.
Ligand data and preparation
The small molecules from the Drug Bank database which passed the druggability test were prepared using the LigPrep module [50] . In total, six molecules were identified in the search, which includes the antibiotic fosfomycin and the natural substrate Uridine-Diphosphate-NAcetylglucosamine. LigPrep is a utility of Schrodinger software suit that combines tools for generating 3D structures from 1D (Smiles) and 2D (SDF) representation, searching for tautomers and steric isomers and performs a geometry minimization of ligands. The ligands were minimized by means of Molecular Mechanics Force Fields (OPLS-2005) [51] with default setting.
Docking protocol
The prepared ligands were docked into the active site of MurA ligase using the GLIDE (Grid-based LIgand Docking with Energetics) module [29] of Schrodinger. Since the binding side or active site residues of the V. cholerae MurA ligase are not known experimentally, so the catalytic residues of the V. fischeri MurA enzyme were located in our protein model and used for receptor grid generation. The ligands were docked initially using the 'standard precision' method. Glide Score is used to predict binding affinity and rank the ligands in database screens, while a composite scoring function E model , which is a combination of energy-grid score, binding affinity predicted by Glide Score and internal strain energy (for flexible docking) for the model is used to select the correctly docked pose. The ligand with the best SP docking scores was then further analyzed by eXtra Precision (XP) docking.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.ygeno.2013.12.002.
